1 not yet recruiting, 1 recruiting, 1 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Cutaneous T-Cell Lymphomas: new trials by email Literature Review of Cutaneous T-Cell Lymphomas trials Research Report on Cutaneous T-Cell Lymphomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Medsyn Biopharma, LLC | 75 | 2026-11-01 | 2026-10-27 |
| Amping up With PemJAK Ruxolitinib, Pembrolizumab - Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma | Phase 2 | Recruiting | Seda S. Tolu | 53 | 2025-12-03 | 2025-12-16 |
| Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome TSEBT, TSEBT and pembrolizumab - Cutaneous T-Cell Lymphomas | Phase 1 | Withdrawn | University of Texas Southwestern Medical Center | 2018-07-24 | 2020-04-22 |
Lymphoma, T-Cell, Cutaneous (3) · Lymphoma, T-Cell, Peripheral (2) · Mycosis Fungoides (2) · Sezary Syndrome (2) · Hematologic Neoplasms (1) · Leukemia, Large Granular Lymphocytic (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm Metastasis (1) · Recurrence (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoma, T-Cell (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Lymphoma, Non-Hodgkin (2) · Breast Diseases (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Squamous Cell (1) · Digestive System Diseases (1)
pembrolizumab (2) · ruxolitinib (1)
Medsyn Biopharma, LLC (1) · Seda S. Tolu (1) · University of Texas Southwestern Medical Center (1)
United States (2)
Krish Patel, MD (1) · Seda Tolu, MD (1)